Patients with early stage high-risk prostate cancer (prostate specific antigen > 20, Gleason score > 7) are at high risk of recurrence following prostate cancer irradiation.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Radiation dose escalation to the prostate may improve biochemical-free survival for these patients. However, high rectal and bladder dose with conventional three-dimensional conformal radiotherapy may lead to excessive gastrointestinal and genitourinary toxicity. Image-guided radiotherapy (IGRT), by virtue of combining the steep dose gradient of intensity-modulated radiotherapy and daily pretreatment imaging, may allow for radiation dose escalation and decreased treatment morbidity. Reduced treatment time is feasible with hypo-fractionated IGRT and it may improve patient quality of life.
Nguyen NP, Davis R, Bose SR, Dutta S, Vinh-Hung V, Chi A, Godinez J, Desai A, Woods W, Altdorfer G, D'Andrea M, Karlsson U, Vo RA, Sroka T. Are you the author?
Department of Radiation Oncology, Howard University, Washington, DC, USA; Department of Radiation Oncology, Michael D. Wachtel Cancer Center, Oskosh, WI, USA; Department of Radiation Oncology, Medicine and Radiation Oncology PA, San Antonio, TX, USA; Department of Radiation Oncology, Martinique University Hospital, Martinique, France; Department of Radiation Oncology, University of West Virginia, Morgantown, WV, USA; Department of Radiation Oncology, Rochester Radiation Oncology Group , Rochester, NY, USA; Department of Radiation Oncology,Akron City Hospital, Akron, OH, USA; Department of Radiation Oncology, Richard A. Henson Institute, Salisbury, ML, USA; Department of Radiation Oncology, Camden Clark Cancer Center, Parkersburg, WV, USA; Department of Radiation Oncology, University Cancer Centers, Houston, TX, USA; Department of Radiation Oncology, Marshfield Clinic, Marshfield, WI, USA; University of Galveston School of Medicine, Galveston, TX, USA; Department of Radiation Oncology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA.
Reference: Front Oncol. 2015 Feb 2;5:18.